HOME >> MEDICINE >> NEWS
New relief for unexplained chest pain

Iowa City, Iowa May 09, 2007 - The discomfort caused by esophageal (non-cardiac) chest pain is often severe, driving many patients to emergency rooms and physicians' offices despite the fact that the ailment has no definable pathology. Although this pain may sometimes be the result of acid reflux disease, when this is absent most patients present hypersensitivity of the esophagus, and a recent study suggests a potential new way of managing this and other symptoms.

The study finds that theophylline, taken either intravenously or orally, appears to reduce esophageal chest pain by relaxing the esophageal wall and decreasing hypersensitivity. Lead author Satish S.C. Rao finds evidence that these beneficial effects may also be influenced by theophylline's actions on adenosine receptors, altering esophageal sensory thresholds at the same time as relaxing the muscles.

Rao notes that "following oral administration, symptomatic improvement was seen in nearly 60 percent of patients, and the drug was reasonably well tolerated," adding that "if a cardiac, pulmonary, musculoskeletal or esophageal source such as acid reflux disease can be excluded, our findings suggest that a trial of theophylline may be effective in relieving chest pain."


'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
9-May-2007


Page: 1

Related medicine news :

1. New study could bring relief to sweltering city slickers
2. New study demonstrates that Lubiprostone may improve symptom relief rates in adults with IBS-C
3. New treatment offers relief from chronic back pain
4. Stenting of abdominal arteries offers welcome relief for intestinal angina
5. Pain relief effectiveness down to mind-set?
6. Louisiana Tech receives award for hurricane-relief efforts
7. FDA approves prescription Zaditor for over-the-counter relief from itchy eyes
8. Tipsheet: Focus on gait training, pain relief, pressure ulcers and hearing aid training
9. New allergy vaccine provides long-lasting hay fever relief after just 6 weeks of shots
10. Experimental ragweed therapy offers allergy sufferers longer relief with fewer shots
11. Brief, high-dose steroid treatment offers extended relief to giant cell arteritis patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/20/2017)... 20, 2017 (PRWEB) , ... ... ... a global provider of enterprise-grade IT operations analytics and application performance monitoring ... one of world’s largest healthcare services providers. , According to Peter Ohrenberger, ...
(Date:7/20/2017)... ... ... Doctors on Liens, the leading network of medical providers working on a ... Russell Horine, DC to their exclusive list of medical professionals. Horine Chiropractic is a ... the clinic director and his son Dr. Lee Horine and daughter-in-law Dr. Natalie Horine ...
(Date:7/20/2017)... ... July 20, 2017 , ... TCGRx announced today ... existing adherence automation lines. The ATP® Mini and InspectRx® Mini are ... standard products, but at a size and price point that can help pharmacies ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... LINET, an ... latest innovation to their product line: the AVE 2 birthing bed. , Perfectly suitable ... bring a new level of comfort and efficiency to every phase of childbirth. The ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... million Health Resources and Services Administration (HRSA) grant to train predoctoral dental students ... care needs in rural and underserved areas. , The Predoctoral Pediatric Training Project ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017  The global market for ... of approximately $394.1 million in 2016.  Although in early ... solid growth, in particular as a result of the ... and the recent introduction of a significant number of ... less-invasive testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
Breaking Medicine Technology:
Cached News: